Innate Pharma
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate is a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-17 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 165.5 KB | |
| 2025-06-17 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 204.3 KB | |
| 2025-06-13 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 179.5 KB | |
| 2025-06-13 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 273.5 KB | |
| 2025-05-27 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 210.2 KB | |
| 2025-05-27 07:00 |
Investor Presentation
Informations privilégiées / Autres communiqués
|
French | 173.9 KB | |
| 2025-05-23 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
|
English | 232.8 KB | |
| 2025-05-23 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 230.4 KB | |
| 2025-05-23 07:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 188.7 KB | |
| 2025-05-19 07:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 181.7 KB | |
| 2025-05-19 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 148.3 KB | |
| 2025-05-15 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 170.4 KB | |
| 2025-05-15 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 123.4 KB | |
| 2025-05-13 07:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 251.1 KB | |
| 2025-05-13 07:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 228.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |